Shanghai Eyed For Second China Drug Review Center
This article was originally published in PharmAsia News
The city that many multinational drug firms call home in China is reportedly contemplating building a regional center for drug evaluation under the China FDA, sharing the burden of the current similar center in Beijing. PharmAsia News talks to a former official and legal expert on the reasons behind, and prospects for, the proposal.
You may also be interested in...
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.